CORD-19:dc97e1de3b69da13f534f15afdcedbf48064c69d / 503546-503998 JSONTXT

{"project":"CORD-19-Sentences","denotations":[{"id":"T59052","span":{"begin":0,"end":452},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Mild to none Not observed Vincristine (low-dose), l-asparaginase, glucocorticosteroids Moderate 7-10 days Melphalan, cisplatin, mitoxantrone, actinomycin D Severe 7-10 days Doxorubicin, cyclophosphamide, vinblastine 1 Granulocyte colony-stimulating factor (G-CSF) (e.g., Neupogen) is a recombinant human product that stimulates the release of neutrophils from the bone marrow, and its use shortens the recovery time after myelosuppressive drug therapy."}

{"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T74","span":{"begin":0,"end":452},"obj":"Sentence"}],"text":"Mild to none Not observed Vincristine (low-dose), l-asparaginase, glucocorticosteroids Moderate 7-10 days Melphalan, cisplatin, mitoxantrone, actinomycin D Severe 7-10 days Doxorubicin, cyclophosphamide, vinblastine 1 Granulocyte colony-stimulating factor (G-CSF) (e.g., Neupogen) is a recombinant human product that stimulates the release of neutrophils from the bone marrow, and its use shortens the recovery time after myelosuppressive drug therapy."}

{"project":"CORD-19-PD-UBERON","denotations":[{"id":"T2317","span":{"begin":259,"end":262},"obj":"Body_part"},{"id":"T2318","span":{"begin":364,"end":375},"obj":"Body_part"}],"attributes":[{"id":"A2317","pred":"uberon_id","subj":"T2317","obj":"http://purl.obolibrary.org/obo/UBERON_0001359"},{"id":"A2318","pred":"uberon_id","subj":"T2318","obj":"http://purl.obolibrary.org/obo/UBERON_0002371"}],"text":"Mild to none Not observed Vincristine (low-dose), l-asparaginase, glucocorticosteroids Moderate 7-10 days Melphalan, cisplatin, mitoxantrone, actinomycin D Severe 7-10 days Doxorubicin, cyclophosphamide, vinblastine 1 Granulocyte colony-stimulating factor (G-CSF) (e.g., Neupogen) is a recombinant human product that stimulates the release of neutrophils from the bone marrow, and its use shortens the recovery time after myelosuppressive drug therapy."}